UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No.)

Filed by a Party other than the Registrant \square

Check	the appropriate box:
	Preliminary Proxy Statement
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
	Definitive Proxy Statement
	Definitive Additional Materials
	Soliciting Material under §240.14a-12
	XERIS BIOPHARMA HOLDINGS, INC. (Name of Registrant as Specified in its Charter)
	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payme	nt of Filing Fee (Check the appropriate box):
\checkmark	No fee required.
	Fee previously paid with preliminary materials.
	Fee computed on table in exhibit required by Item 25(b) per Securities Exchange Act of 1934 Rules 14a-6(i)(1) and 0-11.

Filed by the Registrant \square



Xeris Biopharma Holdings, Inc. Important Notice Regarding the Availability of Proxy Materials

Stockholders Meeting to be held on June 7, 2023

For Stockholders of record as of April 12, 2023

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the meeting, go to: www.proxydocs.com/XERS

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/XERS

Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.



If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 27, 2023.

To order paper materials, use one of the following methods.



INTERNET

www.investorelections.com/XERS

TELEPHONE (866) 648-8133 When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.



If requesting material by e-mail, please send a blan e-mail with the 12 digit control number (located abov in the subject line. No other requests, instructions Of other inquiries should be included with your e-mail requesting material.

Xeris Biopharma Holdings, Inc.

Meeting Type: Annual Meeting of Stockholders

Date: Wednesday, June 7, 2023
Time: 8:00 AM, Central Daylight Time

To be held virtually -- please visit www.proxydocs.com/XERS for additional information on virtual meeting registration.

You must register to attend the meeting online and/or participate at www.proxydocs.com/XERS

SEE REVERSE FOR FULL AGENDA

Xeris Biopharma Holdings, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR ON PROPOSALS 1 AND 2

PROPOSAL

- 1. Election of Directors
 - 1.01 Dawn Halkuff
 - 1.02 John H. Johnson
 - 1.03 Jeffrey W. Sherman
- 2. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023.

NOTE: To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.